Get more information on Plasma Therapy Market - Request Sample Report
The Plasma Therapy Market Size was valued at USD 417.0 million in 2023 and is expected to reach USD 1087.0 million by 2032 and grow at a CAGR of 11.25% over the forecast period 2024-2032.
Growth in the global plasma therapy market is accelerating rapidly due to the increasing incidents of life-threatening diseases, like different types of neurological disorders-chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP), and multifocal motor neuropathy (MMN). The increasing incidents of contagious diseases like hepatitis A and B, tetanus, and rabies will also act as a healthy influence that is believed to change the inclination of the market in the coming years. The geriatric population also has more diminished immune systems and they are more susceptible to infectious diseases, thus adding up the demand for plasma therapy, hence supporting the overall growth in the market. CIDP, which accounts for 0.7 to 10.3 cases per 100,000, involving 1–2 new cases every year, fuels the demand for plasma-based treatments in the Plasma Therapy Market. Plasma therapy also has an indispensable role in the treatment of ITP, where the immune system mistakenly attacks the platelets. Simultaneously, with a prevalence of 1.33 cases per 100,000, Multifocal Motor Neuropathy patients also gain considerably from plasma therapy, thereby fueling the market.
The two major growth drivers for the market are the increasing incidence of orthopedic disorders and androgenic alopecia, diseases that plasma therapy can treat with protein substitution. The development in techniques related to plasma fractionation has allowed the manufacture of multiple plasma-derived therapies and thus life-altering drugs to be administered to patients with chronic and debilitating diseases such as hemophilia and congenital immunodeficiencies. Plasma products have established an indispensable role in the management and prevention of bleeding disorders and autoimmune diseases. Plasma products are major contributors to medical treatment and prophylaxis.
Advances in technology have emerged as a driver in the market. New separator technologies, to give an example, have acquired significant importance in meeting the resultant demand for plasma-derived therapies, just like in the case of the Rika Plasma Donation System. In 2021, for instance, GEA provided separator technology to Biopharma S.A. in Ukraine used for plasma fractionation processes. Other collaborations among pharmaceutical firms in the development of medicines, including in response to public health issues such as that presented by COVID-19, have also increased in the market.
Table 1: Regulatory Landscape for Plasma Therapy in Key Regions
|
Region |
Regulatory Body |
Key Regulations and Guidelines |
|---|---|---|
|
North America (USA) |
FDA |
Approval for PRP treatments in specific uses |
|
Europe (EU) |
EMA |
CE marking requirements for plasma devices |
|
Asia Pacific (Japan, China) |
PMDA, NMPA |
Strict guidelines for blood-derived products |
|
Middle East & Africa |
Ministry of Health (Various) |
Limited regulations, emerging market |
|
Latin America |
ANVISA |
Increasing focus on plasma therapy standards |
Drivers
Increased public awareness and technological advancements enhance the value of plasma-derived treatments in managing severe health conditions.
The surge in COVID-19 cases worldwide has significantly affected the plasma therapy market because the plasma of recovered patients has become more highly valued as a potential treatment for the virus. These are targeting only SARS-CoV-2, and with the positive responses after transfusing such plasma into infected patients, interest in plasma therapy has mounted with its promise in managing an increasingly high level of cases.
An added factor contributing to the demand for plasma therapy is public awareness of diseases and appropriate treatments available. Benefits of plasma-derived therapies towards patients, as informed by healthcare providers, continue increasing their utilization in clinical settings.
Pharmaceutical and biopharmaceutical companies are rapidly expanding collaborations and partnerships driving this market demand. For instance, in November 2022, Australia-based biotechnology company CSL agreed to license Translational Sciences, Inc. with the development of an anti-α2-antiplasmin monoclonal antibody TS23. This candidate aims to be the first to break thrombi responsible for grave conditions such as pulmonary embolism, which is the cause of severe issues like acute ischemic stroke, and its future evaluation in the U.S. within the NAIL-IT Phase II study, assessing the safety in patients with intermediate-risk pulmonary embolism.
The development of new technologies in plasma therapy also assists growth in the market. In March 2021, Grifols, S.A. announced that DG Reader Net, a semi-automated analyzer has been installed to increase pre-transfusion blood type compatibility testing in North America. Such new developments much do towards streamlining the process in plasma therapy and improving patient outcomes, which fuel further growth in the sector.
Restraints
Increasing Adoption of Recombinant Therapies
Safety Concerns Associated with Plasma Products
by Type
In 2023, pure PRP captured almost 40.0% revenue share in the plasma therapy market. Its success is due to it being an effective and handy treatment for almost all medical applications such as orthopedics, dermatology, and dental procedures. Pure PRP contains high concentrations of platelets proven for healing and diminishing the recovery time. The clinical outcomes of Pure PRP have led to the fact that healthcare providers as well as patients prefer it. Besides, new advancements in extracting techniques continue improving the quality and efficacy of Pure PRP, enhancing its position in the marketplace.
The fastest growing one is Leucocyte-Rich PRP, which is expected to grow at a CAGR of 12.0% because of enhanced healing properties as well as added leukocytes that contribute to tissue regeneration. This segment is primarily driven by the demand for more effective treatments, especially in orthopedic and sports medicine applications.
by Source
In 2023, the source category of autologous dominated the market for plasma therapy with a share of around 65.0% in terms of revenue. The high demand for autologous plasma therapies is due to their high safety profile as they are sourced from the patient's blood itself, thus providing a major advantage in terms of safety since there is no risk of disease transmission associated with autologous sources. Autologous therapies also trigger fewer allergic reactions and better overall acceptance among patients, thus making them an ideal choice for most practitioners.
Allogenic sources are the fastest growing area in this category with an estimated growth rate of 10.0%. Due to the demand for easily accessible treatment methods, especially in emergency conditions where direct access to the patient's blood may not be granted, allogenic products are increasingly needed. Coupled with the research and development accompanied by technological advancement, allogenic therapy is secured as a safe and efficient therapeutic option.
by Application
The Orthopedics application segment dominated the plasma therapy market in 2023, accounting for approximately 45.0% of the total revenue. Orthopedics is perceived to be major over the rest due to the increased incidence of sport-related injuries and higher demand for minimally invasive treatments. Plasma therapy is most known for the acceleration of the healing process of joint and soft tissue injuries, making it more in demand by orthopedic practices.
The fastest-growing application is in dermatology, with a projected CAGR of 15.0%. This is due to the high demand for hair restoration and skin rejuvenation treatments through PRP, among others. Such demand is attributed to increased consumer awareness of aesthetic procedures. Innovative applications in dermatology increasingly augment plasma therapy's reach, accounting for higher consumption.
by End User
In 2023, Hospitals & Clinics became the largest end users in the plasma therapy market, accounting for approximately 70.0% of the revenue. Hospitals and clinics are preferred because they have established infrastructure and skilled professionals besides ready access to advanced technologies for plasma therapies. Even more, hospitals are likely the patient's first stop for treatment of conditions such as injuries that often happen among people associated with sports and even orthopedic surgeries that can be treated with plasma therapy.
The research institutions are the most rapidly growing segment, with growth prospects at around 13.0%. Rising research and development activities related to plasma therapy are increasingly driving demand from research institutions. Clinical studies and trials related to plasma-derived treatments, which have the potential to help discover new applications for these treatments, increase the growth due to the validation of researchers of the efficacy and safety of the same in different medical fields.
The market share of North America was the highest in 2023 at 47.8% due to the considerable awareness prevailing in the region and a very robust healthcare infrastructure. The regional market was dominated by North America with the highest market share during 2020 primarily because it houses the leading manufacturers of platelet-rich plasma (PRP) therapy products and has the proactive involvement of research and academic institutions conducting advanced R&D. The high public awareness about the advantages of PRP therapies, the continued good support from the authorities as well as government initiatives to promote plasma therapy in different medical applications are also contributing to growth. Well-established healthcare structures in North America, coupled with the availability of highly skilled professionals, contribute significantly towards market growth.
The Asia-Pacific plasma therapy market is rapidly growing with a surge in government activity in the promotion of plasma therapy as an available treatment. The high population density in the region, coupled with the increasing prevalence of chronic diseases, is a major factor propelling the expansion of this market. Improved healthcare facilities and the active involvement of the government in improving public health form substantial opportunities for growth in this industry. The COVID-19 pandemic has also increased the level of awareness about plasma therapy, which has also become an identified possible treatment for the virus. India would emerge as a leader in the adoption of this therapy. Apart from that, major market players in the region are making significant investments in plasma therapy, driving the growth of the plasma therapy market in Asia-Pacific and defining its prospects in healthcare development.
Need any customization research on Plasma Therapy Market - Enquiry Now
Key Players Offering Plasma Therapy
MTF Biologics
Regen Lab SA
Arthrex, Inc.
Terumo Corporation
Exactech, Inc.
Cambryn Biologics LLC
Global Stem Cells Group, Inc.
Celling Biosciences, Inc.
Key Players Offering Drugs Related to Plasma Therapy
Johnson & Johnson (DePuy Synthes)
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Octapharma
Grifols S.A.
CSL Ltd.
Grifols International S.A.
Kedrion S.p.A.
LFB S.A.
Bio Products Laboratory Ltd.
China Biologic Products, Inc.
Recent Developments
In Oct 2024, Capillot Hair broadened its hair restoration services in Dallas by incorporating Follicular Unit Extraction (FUE) transplants and Platelet-Rich Plasma (PRP) therapy.
In Sept 2024, Cold atmospheric plasma therapy emerged as an innovative treatment for infections associated with Berlin Heart EXCOR pediatric cannulas. This novel approach is gaining attention for its potential to effectively address these challenging infections in young patients.
In May 2023, Dr. John Kahen, the founder of Beverly Hills Med Spa, was awarded a U.S. patent for Smart PRP therapy. This innovative treatment is primarily utilized for hair restoration and also serves various purposes, including skin rejuvenation, addressing skin scarring, and pigmentation issues, and improving skin texture.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 417.0 Million |
| Market Size by 2032 | USD 1087.0 Million |
| CAGR | CAGR of 11.25% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)) • By Source (Autologous, Allogenic) • By Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury, Others) • By End User (Hospitals & Clinics, Research Institutions) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia-Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia-Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | MTF Biologics, Regen Lab SA, Arthrex, Inc., Terumo Corporation, Zimmer Biomet, Exactech, Inc., Cambryn Biologics LLC, Global Stem Cells Group, Inc., Juventix Regenerative Medical LLC, Celling Biosciences, Inc. |
| Key Drivers | • Increased public awareness and technological advancements enhance the value of plasma-derived treatments in managing severe health conditions. |
| Restraints | • Increasing Adoption of Recombinant Therapies • Safety Concerns Associated with Plasma Products |
Ans. The Plasma Therapy market size was valued at USD 417.0 million in 2023.
Ams: The Plasma Therapy market is to grow at a CAGR of 11.25% over the forecast period 2024-2032.
Ans The plasma supply was put under further strain by the COVID-19 epidemic. The unexpected increase in COVID-19 patients has an impact on businesses, suppliers, and owners of platelet-rich plasma (PRP) therapeutic items in Asian economies.
Ans. Arthrex, Terumo Corporation, Exactech, Inc., Johnson & Johnson (DePuy Synthes), MTF Biologics, Ony Biotech Inc., Pfizer Inc. are the key players of the Plasma Therapy Market
Ans. Dermatology During the projection period, the segment is anticipated to have the greatest CAGR.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Application Volume: Production and source volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, by Region
6.2 Market Share Analysis, by Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Plasma Therapy Market Segmentation, by Type
7.1 Chapter Overview
7.2 Pure PRP
7.2.1 Pure PRP Market Trends Analysis (2020-2032)
7.2.2 Pure PRP Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Leucocyte-rich PRP
7.3.1 Leucocyte-rich PRP Market Trends Analysis (2020-2032)
7.3.2 Leucocyte-rich PRP Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Pure Platelet-rich Fibrin (PRF)
7.4.1 Pure Platelet-rich Fibrin (PRF) Market Trends Analysis (2020-2032)
7.4.2 Pure Platelet-rich Fibrin (PRF) Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Leukocyte-rich Fibrin (L-PRF)
7.5.1 Leukocyte-rich Fibrin (L-PRF) Market Trends Analysis (2020-2032)
7.5.2 Leukocyte-rich Fibrin (L-PRF) Market Size Estimates and Forecasts to 2032 (USD Million)
8. Plasma Therapy Market Segmentation, by Source
8.1 Chapter Overview
8.2 Autologous
8.2.1 Autologous Market Trends Analysis (2020-2032)
8.2.2 Autologous Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Allogenic
8.3.1 Allogenic Market Trends Analysis (2020-2032)
8.3.2 Allogenic Market Size Estimates And Forecasts To 2032 (USD Million)
9. Plasma Therapy Market Segmentation, by Application
9.1 Chapter Overview
9.2 Orthopedics
9.2.1 Orthopedics Market Trends Analysis (2020-2032)
9.2.2 Orthopedics Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Dermatology
9.3.1 Dermatology Market Trends Analysis (2020-2032)
9.3.2 Dermatology Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Dental
9.4.1 Dental Market Trends Analysis (2020-2032)
9.4.2 Dental Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Cardiac Muscle Injury
9.5.1 Cardiac Muscle Injury Market Trends Analysis (2020-2032)
9.5.2 Cardiac Muscle Injury Market Size Estimates and Forecasts to 2032 (USD Million)
9.6 Nerve Injury
9.6.1 Nerve Injury Market Trends Analysis (2020-2032)
9.6.2 Nerve Injury Market Size Estimates and Forecasts to 2032 (USD Million)
9.7 Others
9.7.1 Others Market Trends Analysis (2020-2032)
9.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Plasma Therapy Market Segmentation, by End User
10.1 Chapter Overview
10.2 Hospitals & Clinics
10.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
10.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Million)
10.3 Research Institutions
10.3.1 Research Institutions Market Trends Analysis (2020-2032)
10.3.2 Research Institutions Market Size Estimates and Forecasts to 2032 (USD Million)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trends Analysis
11.2.2 North America Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.2.3 North America Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.2.4 North America Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.2.5 North America Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.6 North America Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.2.7 USA
11.2.7.1 USA Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.2.7.2 USA Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.2.7.3 USA Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.7.4 USA Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.2.8 Canada
11.2.8.1 Canada Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.2.8.2 Canada Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.2.8.3 Canada Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.8.4 Canada Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.2.9 Mexico
11.2.9.1 Mexico Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.2.9.2 Mexico Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.2.9.3 Mexico Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.2.9.4 Mexico Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Trends Analysis
11.3.1.2 Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.3.1.3 Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.1.4 Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.1.5 Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.6 Eastern Europe Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.1.7 Poland
11.3.1.7.1 Poland Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.1.7.2 Poland Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.1.7.3 Poland Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.7.4 Poland Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.1.8 Romania
11.3.1.8.1 Romania Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.1.8.2 Romania Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.1.8.3 Romania Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.8.4 Romania Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.1.9 Hungary
11.3.1.9.1 Hungary Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.1.9.2 Hungary Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.1.9.3 Hungary Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.9.4 Hungary Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.1.10 turkey
11.3.1.10.1 Turkey Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.1.10.2 Turkey Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.1.10.3 Turkey Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.10.4 Turkey Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.1.11 Rest of Eastern Europe
11.3.1.11.1 Rest of Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.1.11.2 Rest of Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.1.11.3 Rest of Eastern Europe Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.1.11.4 Rest of Eastern Europe Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2 Western Europe
11.3.2.1 Trends Analysis
11.3.2.2 Western Europe Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.3.2.3 Western Europe Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.4 Western Europe Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.5 Western Europe Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.6 Western Europe Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.7 Germany
11.3.2.7.1 Germany Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.7.2 Germany Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.7.3 Germany Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.7.4 Germany Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.8 France
11.3.2.8.1 France Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.8.2 France Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.8.3 France Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.8.4 France Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.9 UK
11.3.2.9.1 UK Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.9.2 UK Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.9.3 UK Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.9.4 UK Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.10 Italy
11.3.2.10.1 Italy Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.10.2 Italy Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.10.3 Italy Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.10.4 Italy Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.11 Spain
11.3.2.11.1 Spain Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.11.2 Spain Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.11.3 Spain Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.11.4 Spain Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.12 Netherlands
11.3.2.12.1 Netherlands Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.12.2 Netherlands Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.12.3 Netherlands Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.12.4 Netherlands Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.13 Switzerland
11.3.2.13.1 Switzerland Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.13.2 Switzerland Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.13.3 Switzerland Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.13.4 Switzerland Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.14 Austria
11.3.2.14.1 Austria Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.14.2 Austria Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.14.3 Austria Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.14.4 Austria Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.3.2.15 Rest of Western Europe
11.3.2.15.1 Rest of Western Europe Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.3.2.15.2 Rest of Western Europe Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.3.2.15.3 Rest of Western Europe Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.3.2.15.4 Rest of Western Europe Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4 Asia Pacific
11.4.1 Trends Analysis
11.4.2 Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.4.3 Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.4 Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.5 Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.6 Asia Pacific Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.7 China
11.4.7.1 China Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.7.2 China Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.7.3 China Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.7.4 China Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.8 India
11.4.8.1 India Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.8.2 India Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.8.3 India Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.8.4 India Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.9 Japan
11.4.9.1 Japan Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.9.2 Japan Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.9.3 Japan Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.9.4 Japan Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.10 South Korea
11.4.10.1 South Korea Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.10.2 South Korea Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.10.3 South Korea Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.10.4 South Korea Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.11 Vietnam
11.4.11.1 Vietnam Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.11.2 Vietnam Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.11.3 Vietnam Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.11.4 Vietnam Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.12 Singapore
11.4.12.1 Singapore Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.12.2 Singapore Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.12.3 Singapore Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.12.4 Singapore Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.13 Australia
11.4.13.1 Australia Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.13.2 Australia Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.13.3 Australia Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.13.4 Australia Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.4.14 Rest of Asia Pacific
11.4.14.1 Rest of Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.4.14.2 Rest of Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.4.14.3 Rest of Asia Pacific Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.4.14.4 Rest of Asia Pacific Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5 Middle East and Africa
11.5.1 Middle East
11.5.1.1 Trends Analysis
11.5.1.2 Middle East Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.5.1.3 Middle East Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.1.4 Middle East Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.1.5 Middle East Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.6 Middle East Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.1.7 UAE
11.5.1.7.1 UAE Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.1.7.2 UAE Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.1.7.3 UAE Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.7.4 UAE Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.1.8 Egypt
11.5.1.8.1 Egypt Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.1.8.2 Egypt Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.1.8.3 Egypt Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.8.4 Egypt Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.1.9 Saudi Arabia
11.5.1.9.1 Saudi Arabia Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.1.9.2 Saudi Arabia Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.1.9.3 Saudi Arabia Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.9.4 Saudi Arabia Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.1.10 Qatar
11.5.1.10.1 Qatar Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.1.10.2 Qatar Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.1.10.3 Qatar Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.10.4 Qatar Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.1.11 Rest of Middle East
11.5.1.11.1 Rest of Middle East Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.1.11.2 Rest of Middle East Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.1.11.3 Rest of Middle East Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.1.11.4 Rest of Middle East Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.2 Africa
11.5.2.1 Trends Analysis
11.5.2.2 Africa Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.5.2.3 Africa Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.2.4 Africa Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.2.5 Africa Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.6 Africa Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.2.7 South Africa
11.5.2.7.1 South Africa Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.2.7.2 South Africa Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.2.7.3 South Africa Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.7.4 South Africa Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.2.8 Nigeria
11.5.2.8.1 Nigeria Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.2.8.2 Nigeria Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.2.8.3 Nigeria Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.8.4 Nigeria Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.5.2.9 Rest of Africa
11.5.2.9.1 Rest of Africa Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.5.2.9.2 Rest of Africa Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.5.2.9.3 Rest of Africa Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.5.2.9.4 Rest of Africa Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6 Latin America
11.6.1 Trends Analysis
11.6.2 Latin America Plasma Therapy Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
11.6.3 Latin America Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.6.4 Latin America Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.6.5 Latin America Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.6 Latin America Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6.7 Brazil
11.6.7.1 Brazil Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.6.7.2 Brazil Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.6.7.3 Brazil Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.7.4 Brazil Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6.8 Argentina
11.6.8.1 Argentina Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.6.8.2 Argentina Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.6.8.3 Argentina Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.8.4 Argentina Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6.9 Colombia
11.6.9.1 Colombia Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.6.9.2 Colombia Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.6.9.3 Colombia Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.9.4 Colombia Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11.6.10 Rest of Latin America
11.6.10.1 Rest of Latin America Plasma Therapy Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
11.6.10.2 Rest of Latin America Plasma Therapy Market Estimates and Forecasts, by Source (2020-2032) (USD Million)
11.6.10.3 Rest of Latin America Plasma Therapy Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
11.6.10.4 Rest of Latin America Plasma Therapy Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
12. Company Profiles
12.1 Regen Lab SA
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 MTF Biologics
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Arthrex, Inc.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Pfizer Inc.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Teva Pharmaceutical Industries Ltd.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 BioLife Plasma Services
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Grifols S.A.
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Biotest
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Terumo Corporation
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Johnson & Johnson
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Type
Pure PRP
Leucocyte-rich PRP
Pure Platelet-rich Fibrin (PRF)
Leukocyte-rich Fibrin (L-PRF)
By Source
Autologous
Allogenic
By Application
Orthopedics
Dermatology
Dental
Cardiac Muscle Injury
Nerve Injury
Others
By End User
Hospitals & Clinics
Research Institutions
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The MicroRNA Market Size, valued at USD 1.3 Billon in 2023, is expected to reach USD 7.7 Billon by 2032, growing at a 21.1% CAGR.
The Gas Chromatography Market Size was valued at USD 3.48 billion in 2023 and is expected to reach USD 5.47 billion by 2032 and grow at a CAGR of 5.16% over the forecast period 2024-2032.
The Atrial Fibrillation Devices Market size was valued at USD 4.34 Bn in 2023 and is expected to reach USD 16.78 Bn by 2031 and grow at a CAGR of 18.4% over the forecast period of 2024-2031.
The Drug Eluting Stent Market size was estimated at USD 7.80 Billion in 2023 and is expected to reach USD 14.98 Billion by 2031 at a CAGR of 8.5% during the forecast period of 2024-2031.
The Multimodal Imaging Market size was valued at USD 4.43 billion in 2023 and is expected to reach USD 7.43 Billion by 2032, growing at a CAGR of 5.93% during the forecast period of 2024-2032.
The AI in Pathology Market size was valued at USD 1050.18 million in 2023 and is expected to grow to USD 1915.21 million by 2031 and grow at a CAGR Of 7.8% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
